Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00344292 |
Atherosclerosis is a condition that occurs when fatty deposits build up along the inner walls of arteries. New strategies are needed to prevent and treat atherosclerosis. The purpose of this study is to analyze the DNA of participants in two ongoing studies to identify genetic variations responsible for the development of atherosclerosis.
Condition |
---|
Atherosclerosis Cardiovascular Diseases |
Study Type: | Observational |
Study Design: | Case Control, Retrospective |
Official Title: | SNPs and Extent of Atherosclerosis (SEA) Study |
DNA
Enrollment: | 2763 |
Study Start Date: | March 2006 |
Atherosclerosis is a condition in which deposits of fat, cholesterol, and other substances build up along the inner walls of arteries; these deposits are known as plaque. As plaque builds up, it increases the risk of blood clots, heart attack, and stroke. Research has shown that the risk of developing atherosclerosis can be influenced by heredity. However, researchers have been unable to identify the specific genes associated with this risk. Single nucleotide polymorphisms (SNPs) are small genetic variations that can occur within an individual's DNA. In this study, researchers will analyze the DNA of many individuals for differences in SNP patterns. The goal of the study is to determine which SNP patterns are associated with the development of atherosclerosis. The data from this study may lead to new strategies for early identification of high risk individuals who may benefit from aggressive treatment to prevent the development of atherosclerosis.
This study will not recruit any new participants. DNA will be collected and analyzed from participants in two existing studies—the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study and the Multi-Ethnic Study of Atherosclerosis (MESA). DNA from the PDAY participants will be obtained from liver samples gathered during an autopsy following the participants' deaths; DNA from the MESA participants will be obtained from blood collected during routine study visits. There will be no additional study visits for participants, and all DNA samples and study information will be kept confidential. Genetic testing will be performed to determine the association between SNPs and subclinical atherosclerosis, which is a form of the condition prior to the onset of symptoms. The study will evaluate specific variations in SNPs and subclinical disease among different ethnic groups, which may help to explain why certain ethnic groups have higher rates of atherosclerosis. The study will also examine the association between SNPs and other indicators of subclinical and clinical atherosclerosis, including the thickness of arteries, heart calcium levels, and blood pressure levels.
Ages Eligible for Study: | 15 Years to 34 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Subject enrolled in the Pathobiologic Determinants of Atherosclerosis in Youth (PDAY) study
Inclusion Criteria: - Participant in PDAY or MESA
United States, California | |
Cedars-Sinai Health System | |
Los Angeles, California, United States, 90048 | |
United States, Louisiana | |
Louisiana State University | |
New Orleans, Louisiana, United States, 70112 | |
United States, Texas | |
The University of Texas | |
Houston, Texas, United States, 77225 | |
United States, Washington | |
University of Washington | |
Seattle, Washington, United States, 98105 |
Principal Investigator: | David M. Herrington, MD, MHS | Wake Forest University |
Responsible Party: | Wake Forest University School of Medicine ( David Herrington ) |
Study ID Numbers: | 1333, R01 HL080443-01A1 |
Study First Received: | June 23, 2006 |
Last Updated: | February 11, 2009 |
ClinicalTrials.gov Identifier: | NCT00344292 History of Changes |
Health Authority: | United States: Federal Government |
Polymorphism, Genetic Coronary Artery Disease Coronary Arteriosclerosis Polymorphism, Single Nucleotide SNPs |
Arterial Occlusive Diseases Coronary Disease Atherosclerosis |
Vascular Diseases Arteriosclerosis Coronary Artery Disease |
Arterial Occlusive Diseases Atherosclerosis Vascular Diseases Cardiovascular Diseases Arteriosclerosis |